Probably already testing on humans, they don't need any approvals from anyone they just do it. Obviously if results are promising which on mice was 100% successful we can expect some positive feed back and then as leaks occur we will see share price spikes. Just my thoughts. Happy to wait.
THE MORE SAREUM DOES AND KEEPS BUSY WITH MEETINGS, CONTACTS, AND NETWORKING ....the better we can dance with the dreams we all want here ..taking action and guessing wrong GUESSES for spikes in share price is still doing good boys so if anyone has any ideas ..please share with the board its all little steps and everything matters.goodluck
Cambridge medical technology targeting cancer is set to swamp China following a deal between Sareum Holdings and the Hebei Medical University Biomedical Engineering Center (HMUBEC). AIM-listed Sareum, a specialist cancer drug discovery and development business, has signed a co-development agreement with HMUBEC to advance its Aurora+FLT3 cancer programme. HMUBEC has been granted exclusive rights to carry out pre-clinical and clinical studies within Greater China (the People's Republic of China, Hong Kong, Macau and Taiwan) to obtain approval for sales in that territory. Sareum will receive a significant milestone payment once a product receives authorisation for marketing and up to 15 per cent of operating profit from sales generated in Greater China. HMUBEC is an independent research centre operating within Hebei Medical University Science & Technology General Company, which has developed more than 85 therapeutic products and medical devices for the Chinese market since its formation in 1992. Aurora+FLT3 kinase inhibitors have the potential to treat acute myeloid leukaemia (AML, the most common form of adult leukaemia) and various other forms of cancer. Aurora kinase is involved in the control of mitosis (cell division), and FLT3 kinase over-activation is the most common mutation in AML. The pre-clinical development candidate that has been licenced by Sareum to HMUBEC has shown particular promise against a range of haematological cancer models including AML and Acute Lymphoblastic Leukaemia (ALL) with an encouraging early safety profile and positive ADME (absorption, distribution, metabolism, excretion) properties. Sareum was advised and assisted on this agreement by Cambridge, UK based technology brokerage Link China Pharma Solutions. Dr Tim Mitchell, CEO of Sareum Holdings plc, said: “This agreement provides us with significant additional resource, exposure to a major market and the flexibility to undertake our own independent research utilising HMUBEC's findings at any point in the development programme. “HMUBEC also has the capability and resources to advance the Aurora+FLT3 programme from pre-clinical all the way through clinical trials and onto the Chinese market. We believe all this provides a good balance of risk and reward for our shareholders and we look forward to working closely with HMUBEC.” Professor Donggang Liu, Deputy General Manager of the Hebei Medical University Science & Technology General Company, said: “We have been very impressed with the results of the studies undertaken on Sareum's Aurora+FLT3 programme so far and we have real confidence in the programme's potential to develop a world class drug to treat several forms of blood cancer. “HMUBEC has significant resources and expertise to expedite this research programme, and we look forward to commencing work on this very exciting compound.” • PHOTOGRAPH SHOWS: Sareum CEO, Dr Tim Mitchell Related Articles Cambri
The largest buy has been 1.4m so nothing to really get your teeth into at present.Also only 5 mm,s on today instead of 6 and a 15.4% spread,but nice to see movement in the old girl.Good news elsewhere in from neighbours which is also filtering across.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.